NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brok ...

Core Points - Royalty Pharma plc will report its second quarter 2025 financial results on August 6, 2025, before U.S. financial markets open [1] - A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day [1][2] Company Overview - Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [3] - The company collaborates with various innovators, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [3] - Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and others, as well as 16 development-stage product candidates [3]

Company Overview - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company leverages its expertise in metabolism to create innovative therapeutics aimed at improving patients' lives [3] Clinical Programs - Viking's clinical programs include VK2735, a dual agonist of GLP-1 and GIP receptors, currently evaluated in a Phase 3 obesity program with two trials (VANQUISH-1 and VANQUISH-2) [3] - VK2735 has shown an encouraging safety and tolerability profile along with positive clinical benefits in Phase 1 and Phase 2 trials [3] - An oral formulation of VK2735 is also being evaluated in a Phase 2 trial for obesity [3] - VK2809, a small molecule selective thyroid hormone receptor beta agonist, has achieved primary and secondary endpoints in a Phase 2b study for NASH and fibrosis [3] - In a Phase 2a trial for NAFLD and elevated LDL-C, VK2809 demonstrated statistically significant reductions in LDL-C and liver fat compared to placebo [3] - The company is developing dual amylin and calcitonin receptor agonists (DACRAs) for obesity and metabolic disorders [3] - VK0214, another small molecule selective thyroid hormone receptor beta agonist, is in development for X-ALD and has shown safety and significant reductions in VLCFAs in a Phase 1b trial [3] Upcoming Events - Viking Therapeutics will release its financial results for Q2 2025 after market close on July 23, 2025 [1] - A conference call to discuss these results and corporate updates is scheduled for July 23, 2025, at 4:30 p.m. Eastern Time [2]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks wit ...

Half-Year Report on Liquidity Contract with Invest Securities NANTES, France - July 16, 2025, 6:00pm CET – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following assets were recorded on the liquidity account as of June 30, 2025: As a reminder, at December 31, 2024, the following assets were recorded on the liquidity account: Forward-looking statements This press release contains express or implied information and statements that might be deemed forward- looking ...

Core Viewpoint - Tevogen Bio Holdings Inc. is expanding its AI-driven platform, Tevogen.AI, to enhance patient data integration for clinical trial participant identification, aiming to accelerate the development of personalized T cell therapies [1][2][3] Group 1: Tevogen.AI and PredicTcell™ - Tevogen.AI, supported by Microsoft and Databricks, will analyze electronic health records and real-world patient data to identify potential clinical trial participants [2] - The integration of patient data with the PredicTcell™ model is expected to enhance the ExacTcell™ pipeline development [2][3] Group 2: Clinical Trial Efficiency - Tevogen.AI aims to improve clinical trial efficiency, scalability, and inclusivity by rapidly identifying and enrolling suitable patients [3] - The initiative is designed to address critical bottlenecks in clinical development, potentially accelerating time-to-market for new therapeutic interventions [3][6] Group 3: Strategic Goals - The company’s mission focuses on achieving commercially attractive, economically viable, and cost-effective personalized T cell therapies [3] - By enhancing patient outcomes and expediting therapeutic approvals, Tevogen.AI seeks to provide a foundation for commercial success and investment growth [3]

Investors hunting for firms with massive growth potential often look to trending industries, which are primed to benefit from near-term hype and, in many cases, an influx of demand and capital. In mid-2025, two of the most promising of these industries are rooted in artificial intelligence (AI): AI-based consumer engagement and autonomous vehicles. A third opportunity lies in the biotech sector, specifically companies advancing psychedelic-based therapies for mental health. While investing in early-stage in ...

Core Insights - OKYO Pharma Limited announced positive top-line data from an 18-patient Phase 2 trial of urcosimod for treating neuropathic corneal pain (NCP), a condition with no FDA-approved therapy [1][8] - The trial demonstrated significant pain reduction in patients treated with urcosimod compared to placebo, indicating its potential effectiveness [4][5] Trial Details - The Phase 2 trial was a randomized, double-masked, placebo-controlled study conducted at Tufts Medical Center in Boston, MA, led by Dr. Pedram Hamrah [2][12] - The primary endpoint was the change in mean pain scores from baseline to the end of treatment, measured by a Visual Analogue Scale (VAS) [3] Results Summary - In the per-protocol population, the mean pain score change was 5.5 for the 0.05% urcosimod group versus 2.75 for the placebo group, showing a delta difference of 2.75 [4] - 75% of patients in the urcosimod group achieved over 80% improvement in pain severity, with significant reductions observed as early as Week 4 [8] - In the intent-to-treat population, 67% of patients in the urcosimod group showed greater than 50% improvement in pain compared to 33% in the placebo group [5] Statistical Significance - A statistically significant reduction in mean pain scores was observed in the urcosimod group (p-value = 0.025), while the placebo group also showed improvement (p-value = 0.035) [4][8] - The drug-effect size for urcosimod compared to placebo at week 12 demonstrated a strong treatment effect (Cohen-d value > 1.2) [6] Future Plans - Following the trial, OKYO plans to meet with the FDA to discuss next steps for urcosimod, which has received Fast Track designation for treating NCP [8] - The company is also considering the "Expanded Access" program for patients who completed the trial [9] About Urcosimod - Urcosimod is a lipid conjugated chemerin peptide agonist designed to treat ocular diseases, showing anti-inflammatory and pain-reducing activities in preclinical models [13] - The drug has previously shown efficacy in a Phase 2 trial for dry eye disease, indicating its potential across multiple ocular conditions [10]

Core Viewpoint - All-trans retinoic acid (ATRA) is a key active derivative of vitamin A with extensive clinical application value, but mainstream manufacturers like BASF and DSM still rely on traditional chemical synthesis methods, which pose environmental challenges and do not meet green chemistry requirements [1][3]. Group 1: Research Breakthroughs - The team from the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, achieved a breakthrough by engineering Saccharomyces cerevisiae to produce ATRA at a fermentation yield of 1.84 g/L, providing a green solution for constructing a self-controlled vitamin industry chain [3][8]. - The research utilized a multi-faceted metabolic engineering strategy, optimizing chassis construction, module selection, cellular factory upgrades, and fermentation processes to achieve this yield [8]. Group 2: Metabolic Engineering Strategy - The initial focus was on creating a high-yield chassis for β-carotene, the precursor for ATRA, by screening genes from Xanthophyllomyces dendrorhous, leading to the construction of the Car09 strain with a β-carotene yield of 129.4 mg/L [5][6]. - The best combination for ATRA synthesis was identified as a β-carotene dioxygenase from marine bacteria and mouse retinaldehyde dehydrogenase, achieving 98.1 mg/L ATRA, although significant residual β-carotene indicated limitations in synthesis [6][7]. Group 3: Industrial Adaptation and Optimization - Four-dimensional collaborative modifications were implemented to address efficiency bottlenecks, including overexpressing transcription factors to enhance endoplasmic reticulum activity, balancing NADPH/NAD⁺ levels, and improving substrate supply, resulting in a 49.2% increase in ATRA yield [7][8]. - The development of a two-phase extraction fermentation process, combining glucose growth with ethanol and galactose induction, led to the successful production of ATRA at 1.84 g/L in a 5L fermenter [8]. Group 4: Industry Conference - The SynBioCon 2025 conference, scheduled for August 20-22 in Ningbo, will focus on the intersection of AI and biological manufacturing, exploring trends in green chemistry, new materials, future food, agriculture, and cosmetic ingredients [10][12].

CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants will have an exercise price of $1.32 per share, will be immediately exercisable ...